Kymera Therapeutics' STAT3 Degrader KT-333 and IRAKIMiD Degr

Kymera Therapeutics' STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor... | June 14, 2023

Related Keywords

Switzerland , Watertown , Massachusetts , United States , Lugano , Ticino , Boston , Parco Ciani , Chris Brinzey , Bruce Jacobs , Todd Cooper , Nello Mainolfi , Adam Olszewski , Nasdaq , Kymera Therapeutics Inc , Lifespan Cancer Institute , Corporate Affairs , Boston Globe , Exchange Commission , International Conference On Malignant Lymphoma , Irakimid Program , International Conference , Malignant Lymphoma , Refractory Lymphomas , Large Granular Lymphocytic Leukemia , Marquee Parco , Rhode Island , Fierce Biotech , Boston Business Journal , Private Securities Litigation Reform Act , Kymera Therapeutics , Kymera Therapeutic , Quarterly Report , Financial Officer , Vice President ,